|Dr. William Stuart Marshall Ph.D.||Co-Founder, Pres, CEO & Director||637k||N/A||1964|
|Dr. Paul D. Rubin||Exec. VP of R&D||508.4k||N/A||1954|
|Eric N. Olson||Co-Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Dr. Michael R. Bristow||Co-Founder & Member of the Scientific Advisory Board||N/A||N/A||1945|
|Dr. Marvin H. Caruthers||Scientific Advisory Board Member||N/A||N/A||1940|
Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. The company has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Servier for the development of MRG-110. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.
Miragen Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.